Tumor mutational load predicts survival after immunotherapy across multiple cancer typesRobert Samstein, Ronald P. DeMatteo, Antonio Omuro et al.|Nature Genetics|2019Cited by 4.4k
Nivolumab plus Ipilimumab in Advanced MelanomaJedd D. Wolchok, Mario Sznol, Harriet M. Kluger et al.|New England Journal of Medicine|2013Cited by 4.2k
Cross-presentation of Disialoganglioside GD3 to Natural Killer T CellsDianna Wu, Paul B. Chapman, Neil H. Segal et al.|The Journal of Experimental Medicine|2003Cited by 274
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancerMargherita Ambrosini, Filippo Pietrantonio, Benoı̂t Rousseau et al.|Annals of Oncology|2024Cited by 73
COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancerNeil H. Segal, Josep Tabernero|British Journal of Cancer|2024Cited by 12